ASN: Difelikefalin Improves Itch in CKD-Linked Pruritus

TUESDAY, Nov. 12, 2019 -- For patients undergoing hemodialysis who have moderate-to-severe pruritus, difelikefalin is associated with a significant reduction in itch intensity and improvement in itch-related quality of life, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Ashima Ravindran, Rajesh Peringanazhi Kunnath, Anjali Sunny, Binoo VimalIndian Journal of Palliative Care 2020 26(3):281-286 Background: Uremic pruritus (UP) affects many patients suffering from chronic kidney disease (CKD) and has a negative impact on the quality of life. The severity of UP ranges from sporadic discomfort to complete restlessness during both day and night time. It has become increasingly evident that central transmission and sensitization processes similar to those observed in chronic pain are important mechanisms of pruritus. Methodology: This was a randomized single-blind prospective-interventional stu...
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
Pruritis is common for hemodialysis patients with end-stage kidney disease, but an opioid receptor modulator could provide some relief, a new phase 3 study shows.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news
Nature Reviews Nephrology, Published online: 27 January 2020; doi:10.1038/s41581-020-0251-3The KALM-1 randomized double-blind placebo-controlled phase III trial showed that intravenous difelikefalin, a selective κ-opioid receptor agonist, significantly reduces itch intensity in haemodialysis patients with uraemic pruritus. However, 49% of difelikefalin-treated patients showed no improvement. In light of the increasing number of patients with end-stage renal disease, additional treatments are sorely needed.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research
The objective was to determine whether changes in parathyroid hormone (PTH) levels are associated with changes in symptoms within this patient population.Study DesignProspective cohort.Setting &Participants165 adults with hyperparathyroidism secondary to kidney failure diagnosed, a range of dialysis vintages, and receiving regular hemodialysis from a US single-provider organization.ExposureChange in PTH levels over 24 weeks.Outcomes19 putative symptoms of secondary hyperparathyroidism measured up to 4 times using a self-administered questionnaire that assessed severity on a 5-level ordinal scale.Analytical ApproachLong...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Conclusion and Future Directions G protein bias may either be affinity/potency-dominant or efficacy-dominant (Table 1). A potential concern is that, despite using the same cellular assays, variations in agonist potency were determined by different, or even the same labs, potentially due to differences in expression levels of the receptor and signaling proteins that occurred during cell passaging. For example the reported arrestin recruitment potency for U69,593 has been reported to be as low as 67.7 nM (Spetea et al., 2017) and as high as 410 nM (Dunn et al., 2018), similarly for U50,488 potency has ranged from 36 to 1000...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: Better skin management is needed for itch in patients with ESRD or CKD. Moisturizing and lifestyle factors are important. Topical or oral medications may also be used. Nalfurafine, a κ receptor agonist, is now available in Japan for the treatment of uremic pruritus in these patients.Blood Purif 2019;47(suppl 2):1 –5
Source: Blood Purification - Category: Hematology Source Type: research
A 51-year-old woman with a history of end-stage renal disease, on hemodialysis for 4years, hypertension and diabetes mellitus type II presented with an extremely itchy diffuse skin rash that she initially noticed two weeks prior to presentation. The itching was significant enough to impair her quality of life and she has tried applying various over the counter anti-itch creams without much relief. Examination of the skin was notable for diffusely scattered blackish hyperpigmented, dome-shaped, umbilicated papules, some coalescing into plaques on the trunk and extremities.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
A 51-year-old woman with a history of end-stage renal disease, hypertension, and diabetes mellitus type 2 who had been on hemodialysis for 4 years presented with an extremely itchy diffuse skin rash that she initially noticed 2 weeks prior to presentation. The itching was significant enough to impair her quality of life, and she had tried applying various over-the-counter anti-itch creams without much relief. Examination of the skin was notable for diffusely scattered blackish hyperpigmented, dome-shaped, umbilicated papules, some coalescing into plaques on the trunk and extremities.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
This study demonstrates a high mortality in HD patients; however, mortality depends on itch intensity, not on the occurrence of CI itself. PMID: 30673111 [PubMed - as supplied by publisher]
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
Conclusion: Improvement of sleep quality and quality of life among patients with CKD-associated pruritus requires great importance. This study aims to improve the quality of sleep and quality of life among patients with hemodialysis suffering from CKD-associated pruritus.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
More News: Dialysis | Hemodialysis | Itchiness | Pharmaceuticals | Study